While skills shortages present one of the main challenges to the biopharma industry, North Carolina believes its investments in the life science ecosystem have given it a ‘multiple decade jumpstart’ in building a successful biopharma hub for both manufacturing...
Contract Research Organization (CRO) Texcell has held a breaking ground ceremony for a new facility in Frederick, MD.
Syngene International has inked a non-exclusive partnering agreement with the emerging immuno-oncology company Zumutor Biologics after collaborating for more than a year.
Charles River says increased demand for biologics services prompted its recent Devon Park facility acquisition, bringing its Pennsylvania site count to three
Charles River Laboratories says it is positioning itself to take advantage of growing demand for biological services.
Cel-Sci has responded to the partial clinical hold imposed on a Phase III trial of its candidate head and neck cancer cell therapy Multikine in September.
Biologics manufacturing and testing activities helped Charles River Laboratories grow in Q3 and will drive further gains say analysts.
Cel-Sci has received written confirmation the US FDA has placed a late stage trial of its cancer cell therapy Multikine on partial clinical hold a month after agency first raised concerns.
PPD has added 4,300 square feet of new laboratory space for analytical testing of biopharmaceuticals and inhalation devices to the company’s Athlone, Ireland-based GMP facility.
Sartorius has expanded its bio-analytics capabilities through the $90m (€81m) acquisition of IntelliCyt.
Demand for biological products has driven recent investments in vaccine manufacturing and cell banking, says Charles River Laboratories.
The new collaboration aims to advance a workflow solution for biologics quantification.
BioPharmaSpec has set up business development teams for the Indian and Asia-Pacific markets and predicted increased demand for biosimilar characterisation services.
Charles River has reported strong Q3 sales despite weakness in Japan and plans to grab space in emerging early discovery, bio-testing and Chinese markets.
China’s ShangPharma is building a $60m (€53m) single-use biologics manufacturing plant in Qidong, to be operated by its CMO subsidiary.
TxCell is set to expand a trial of its candidate Crohn’s disease cell therapy to the US after the FDA accepted its IND application.
The US FDA has reached out to industry for comments on the use of interchangeability data in the submission of biosimilars through the 351(k) pathway.
Collaboration does not mean drugmakers have started playing nice, it’s just that the pain of shared problems has become unbearable according to TransCelerate Biopharma CEO, Dalvir Gill.
Almost all of the biosimilars currently approved have been developed using a third-party research organisation according to a survey from the Association of Clinical Research Organizations (ACRO).
Charles River Labs (CRL) has singled out China as an area of “disproportionate growth” in biologics R&D and says it is on the hunt for preclinical acquisitions in the region.
Biosimilar clinical trials are increasing but levels of physician oversight and regulatory decisions are still hurdles to overcome, say Parexel, PPD and Vince & Associates.
Ireland-based CRO Icon unveiled higher than expected revenue and backlog increases in 2012 when compared to 2011, and the company expects even stronger results in 2013.
CiToxLAB says strong revenue growth in 2012 was due to a new global status following its acquisition of Lab Research.
Parexel may be willing to act as a matchmaker for the small and midsized developers that work with its new BioPharm unit according to COO Mark Goldberg.
Outsourcing-Pharma.com presents its weekly low down of the movers and shakers in the world of pharmaceuticals, including news from Parexel, Ricerca, and CSC.
US CRO Pharmaceutical Product Development (PPD) predicts that new CEO Dave Simmons' ‘pharmaceutical industry experience’ gained at Pfizer will be an asset in guiding partnerships.
A patent loss-fuelled surge in big pharma outsourcing will push the European CMO market through the $20bn barrier by 2018, analysis claims.
CROs still seen as good investment says leading banker
The CRO industry is still considered a good long-term investment and the clinical services segment is set to continue its dominance thanks to sponsor R&D spending, says leading banker.
WuXi buys two Chinese CROs in clinical trial expansion
WuXi PharmaTech has expanded into Phase I-IV clinical trial services through the acquisition of two China-based CROs.
vivoPharm branch out in US with MPI partnership and new Hershey office
vivoPharm has extended its oncology offering after striking up an alliance with MPI Research.
DavosPharma teams with Immunologix on 100% human MAbs for discovery
Chemistry services provider DavosPharma has added 100 per cent human antibodies to its discovery offering through a new alliance with Immunologix.
PPD expands consulting services into four new areas
North Carolina, US-based contract research organisation (CRO), PPD, has expanded its product development consulting services into four new areas.
Biobetters a big opportunity for biopharm and CROs
Biobetters, more than biosimilars, are the big opportunity for biopharm and CROs hoping to profit from biologics patent expirations, say experts.
Agilent buys Biocius Life Sciences for undisclosed amount
Agilent Technolgies, the Santa Clara, US-based scientific instrument manufacturer, has acquired instrument manufacturer and contract research organisation (CRO), Biocius Life Sciences, for an undisclosed amount.
Parexel sees Q2 revenue grow, but cuts 2011 outlook
US contract research organisation (CRO) Parexel has cut its 2011 guidance, citing slower backlog conversion from projects generated by “strategic partnerships” as basis for the revision.
Merck Millipore adopts Gyros’ early-stage assay tech
Merck Millipore says Gyros’ Gyrolab xP workstation will be a competitive advantage for its contract immunogenicity, pharmacokinetics and cGMP testing offering for the biopharmaceutical industry.
Latest deals and developments in the CRO space
Outsourcing-pharma presents a round-up of recent developments in the contract research sector, with news from Quintiles, Bioclinica and Cyprotex.
Lab Research lands 5 new “top 35” pharma clients
Preclinical CRO Lab Research says new contracts are a sign of continuing recovery in market as well as firm’s ability to attract broader clientele base.
Almac teams on X-ray data analysis; US plant nears completion
Almac hopes University College Cork solid state chemistry accord will bypass crystallisation hurdles and accelerate drug development.
GBI, Hyprocell collaborate to offer cell line development
CMO Goodwin Biotechnology Inc (GBI) is collaborating with Hyprocell to help clients that need manufacturing services but have a sub-optimal cell line producing low concentrations.
NexACT shows preclinical SR potential
CRO NexMed says new data from preclinical trials show that its NexACT delivery technology can act as a sustained release “depot” for drugs like insulin and taxol.
Parexel allies with Proteome to boost biomarker offering
Parexel has formed an alliance with Proteome Sciences to enhance its biomarker capabilities, allowing it to help clients make earlier assessments of new compounds in development.
MPI and Bioject form needle-free pact
US preclinical CRO MPI Research has formed an alliance with Oregon-based needle-free delivery specialist Bioject Medical Technologies.
Piramal expands contract services and research
India-based Piramal Healthcare has extended the range of early phase drug product development and manufacturing on offer at its Morpeth, UK facility.